for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arrowhead Pharmaceuticals Inc

ARWR.OQ

Latest Trade

32.98USD

Change

0.00(0.00%)

Volume

282,815

Today's Range

32.07

 - 

33.50

52 Week Range

10.42

 - 

36.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
32.98
Open
32.51
Volume
282,815
3M AVG Volume
27.76
Today's High
33.50
Today's Low
32.07
52 Week High
36.75
52 Week Low
10.42
Shares Out (MIL)
95.30
Market Cap (MIL)
3,102.05
Forward P/E
43.59
Dividend (Yield %)
--

Next Event

Arrowhead Pharmaceuticals Inc Analyst R&D Day

Latest Developments

More

Arrowhead Collaborator Janssen Begins Reef-1 Phase 2B Combination Study In Patients With Chronic Hepatitis B Infection

Arrowhead Pharmaceuticals Qtrly Earnings Per Share $0.21

Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-ANG3

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Industry

Biotechnology & Drugs

Contact Info

225 S Lake Ave Ste 1050

+1.626.3043400

http://arrowheadpharma.com/

Executive Leadership

Douglass Bruce Given

Chairman of the Board

Christopher Richard Anzalone

President, Chief Executive Officer, Director

Kenneth Allen Myszkowski

Chief Financial Officer

Bruce D. Given

Chief Operating Officer

Patrick C. O'Brien

General Counsel

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.2K
EPS (USD)

2016

-1.340

2017

-0.470

2018

-0.650

2019(E)

0.747
Price To Earnings (TTM)
71.20
Price To Sales (TTM)
22.68
Price To Book (MRQ)
13.70
Price To Cash Flow (TTM)
61.92
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
25.52
Return on Equity (TTM)
20.24

Latest News

Latest News

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc <ARWR.O> said on Thursday Johnson & Johnson <JNJ.N> would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion (2.8 billion pounds), sending its shares...

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.

BRIEF-Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline

* ARROWHEAD PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON EXPANDING CARDIOMETABOLIC PIPELINE

BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 SECOND QUARTER RESULTS

BRIEF-Arrowhead Pharmaceuticals Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV

* ARROWHEAD BEGINS DOSING IN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Arrowhead Begins Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD BEGINS DOSING IN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE Source text for Eikon: Further company coverage:

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE

BRIEF-Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT

* ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B Source text for Eikon: Further company coverage:

BRIEF-Arrowhead Pharmaceuticals Reports Fiscal 2018 Q1 Results

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 FIRST QUARTER RESULTS

BRIEF-Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arrowhead Pharma Announces Proposed Underwritten Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Silence Therapeutics ‍Sells Further Stake In Arrowhead Pharmaceuticals ​

* SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.

BRIEF-Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV

* ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV Source text for Eikon: Further company coverage:

BRIEF-Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT

* ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT

BRIEF-Silence Therapeutics Says Sold Further Part Of Holding In Arrowhead Pharmaceuticals Inc

* HAS SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.

BRIEF-Silence Therapeutics Says Sold Part Of Holding Of Common Shares In Arrowhead Pharmaceuticals

* THAT IT HAS SOLD PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC

BRIEF-Silence Therapeutics Plc Reports 6.4 Pct Stake In Arrowhead Pharmaceuticals As Of Nov 29

* SILENCE THERAPEUTICS PLC REPORTS 6.4 PERCENT STAKE IN ARROWHEAD PHARMACEUTICALS INC AS OF NOVEMBER 29 - SEC FILING

BRIEF-Arrowhead Qtrly loss per share $0.07

* Qtrly revenue $9.3 million versus $39,583 Source text for Eikon: Further company coverage:

BRIEF-Arrowhead reports Q2 revenue $9 million

* Q2 revenue $9 million versus $43,750 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up